TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3292710
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg orally twice a day
Study: 8049998
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy or chemoradiotherapy
Study: 26675768
Drug: Yellow cassava
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow cassava (mean content: 1460 μg β‐carotene/d)
Study: 26675768
Drug: β‐carotene supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐carotene supplement (1053 μg/d)
Study: 26675768
Drug: White cassava
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White cassava and placebo supplement (control group)
Study: 24813595
Drug: Cinnamon supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplements (1.5 g/d)
Study: 18812344
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) morphine sulfate interpleurally for 24 hours
Study: 16047469
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg bd for 12 weeks (n = 6)
Study: 12496063
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day of red clover-derived dietary isoflavones
Study: 7480524
Drug: ECTx3 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECTx3 (three times weekly electroconvulsive therapy)
Study: 2126420
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g MCT/LCT fats twice weekly
Study: 2126420
Drug: 0.7 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g/kg body weight per day MCT/LCT fats
Study: 2126420
Drug: 1.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/kg body weight per day MCT/LCT fats
Study: 760752
Drug: BW501 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW501 100 mg
Study: 760752
Drug: BW501 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW501 10 mg
Study: 760752
Drug: BW501 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW501 2 mg
Study: 30449171
Drug: Personalized diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized diet (1.2‐1.5 g/kg of protein, 30% of energy from fat, 55‐60% of energy from carbohydrate), face to face nutrition education, pamphlet with nutrition information
Study: 28586607
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for 5 days
Study: 28586607
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment for 5 days
Study: 20673892
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human chorionic gonadotropin (hCG)
Study: 17404369
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (2 cycles of carboplatin AUC 6 and paclitaxel 200 mg/m2 every 21 days) followed by concurrent chemoradiotherapy (66 Gy of chest radiotherapy with carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly)
Study: 17404369
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy alone (66 Gy of chest radiotherapy with carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly)
Study: 15798610
Drug: Intravenous fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fibrinolysis (IVF) with urokinase 900,000 units
Study: 5484103
Drug: High-arousal group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-arousal group (exposed to infantile oral objects)
Study: 30915458
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CAS4, CAS5, CAS6)
Study: 26453108
Drug: Step III
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step III analgesics
Study: 23860019
Drug: Real PKP
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real PKP treatment (1 treatment weekly for 5 weeks)
Study: 23860019
Drug: Sham PKP
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham PKP treatment (1 treatment weekly for 5 weeks)
Study: 19170232
Drug: Low-dose CAF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CAF (300 mg/m(2), 30 mg/m(2), 300 x 2 mg/m(2) over 4 cycles)
Study: 19170232
Drug: Standard-dose CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CAF (400 mg/m(2), 40 mg/m(2), 400 x 2 mg/m(2) over 6 cycles)
Study: 19170232
Drug: High-dose CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CAF (600 mg/m(2), 60 mg/m(2), 600 x 2 mg/m(2) over 4 cycles)
Study: 16515705
Drug: Alternating ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alternating ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg)
Study: 16515705
Drug: Alternating ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alternating ibuprofen and acetaminophen
Study: 11258130
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac-sodium by short time i.v.-infusion (30 min)
Study: 9190982
Drug: ip Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ip Carboplatin 400 mg/m2 Day 1 q 28 days (CBDCA)
Study: 9190982
Drug: ip interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: ip interferon‐alpha 25 x 10(6) U Day 1 + ip carboplatin 400 mg/m2 Day 2 q 28 days (CBDCA + IFN)
Study: 29485527
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use among women with moderate to severe depressive symptoms
Study: 15848601
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 to 50 mg/day)
Study: 15848601
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 to 8 mg/day)
Study: 15848601
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 to 40 mg/day)
Study: 10527967
Drug: Mutational screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutational screening of prostaglandin F2alpha receptor
Study: 8577020
Drug: Drinks with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinks with increasing carbohydrate content (45 to 90 g/L) at constant osmolarity (330 mOsm/kg)
Study: 8577020
Drug: Drinks with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinks with constant carbohydrate content (60 g/L) but varying osmolarity (243 to 374 mOsm/kg)
Study: 22832887
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with a stainless steel 3.5‐mm reconstruction plate
Study: 15728051
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume infusion (2 mL/kg per hour fasting) of compound sodium lactate solution
Study: 15728051
Drug: Small volume
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small volume infusion (3 mL/kg) of compound sodium lactate solution
Study: 3041358
Drug: Sandoglobulin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandoglobulin (500 mg/kg)
Study: 17956570
Drug: Implant exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant exposure
Study: 12115019
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (50 g)
Study: 9385113
Drug: Treatment under
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment under non-identifiable assumptions
Study: 9385113
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect estimation
Study: 2571864
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (50 mU/kg per hour)
Study: 2571864
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (50 mU/kg per hour)
Study: 354938
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Clonazepam and Baclofen
Study: 30564806
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of dental implants with SLActive surface
Study: 30564806
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of dental implants with SLActive surface
Study: 18201432
Drug: Traditional aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional aerosol therapy (Group A)
Study: 18201432
Drug: Abbreviated aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abbreviated aerosol therapy with new spacer mouth mask (Group B)
Study: 15716985
Drug: Phenobarbital (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (5 mg/kg/day for first 3 days)
Study: 12093850
Drug: Day 5
Normalized name: One-A-Day 50+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 5 embryo transfer (after culture in sequential media)
Study: 10069787
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg body weight of 0.9% saline infusion
Study: 10069787
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion in normal subjects
Study: 7568536
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (individual)
Study: 2208537
Drug: Lidocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (0.2 ml one per cent intradermally)
Study: 156069
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of chemotherapeutic agents (15 drugs)
Study: 28294174
Drug: EPA+DHA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA (4 g/day)
Study: 24497661
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBT‐I)
Study: 19335986
Drug: Capsule metadoxine
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule metadoxine 500mg tid po
Study: 15321816
Drug: AB-yogurt (10^7
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-yogurt (10^7 colony-forming units of both Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12/mL) twice daily after a meal for 6 weeks
Study: 30064713
Drug: DCCT intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DCCT intensive therapy
Study: 29409289
Drug: Suture-tape augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture-tape augmentation
Study: 26834213
Drug: Baricitinib 8
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib 8 mg
Study: 26800231
Drug: Baricitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (all doses except 2 mg)
Study: 26800231
Drug: Baricitinib 8
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib 8 mg and 10 mg
Study: 22451206
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of liquefied brain tissue (5 days per week)
Study: 7753339
Drug: Naloxone (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (125 micrograms/kg) and AVP (10 units) combined administration
Study: 7753339
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg) with naloxone and AVP
Study: 27053335
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium (25 mg/kg administered rectally)
Study: 26141305
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of r-hFSH plus r-hLH (Pergoveris)
Study: 26141305
Drug: r-hFSH monotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hFSH monotherapy (GONAL-f)
Study: 23358057
Drug: Supportive text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive text messages delivered twice daily for three months
Study: 21333087
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion during pressure support ventilation
Study: 21333087
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during pressure support ventilation
Study: 15606399
Drug: Ultrase MT12
Normalized name: Ultrase MT12 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrase MT12 (12,000 lipase units per capsule)
Study: 15606399
Drug: Ultrase MT20
Normalized name: Ultrase MT20 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrase MT20 (20,000 lipase units per capsule)
Study: 11416689
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of low-dose aspirin, calcium, or other dietary supplements for the prevention of pre-eclampsia
Study: 7983226
Drug: Desensitization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitization treatment to lessen dietary restraint anxiety
Study: 16200335
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g/day)
Study: 26004162
Drug: Goserelin (GnRHa)
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin (GnRHa) 3.6 mg implant
Study: 23615868
Drug: GXR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GXR and LDX in combination
Study: 17111469
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric ropivacaine 10.5 mg
Study: 17111469
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric ropivacaine 12 mg
Study: 17111469
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric ropivacaine 13.5 mg
Study: 17111469
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric ropivacaine 15 mg
Study: 11182337
Drug: Neoadjuvant estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) for three cycles, followed by radical prostatectomy.
Study: 11182337
Drug: Neoadjuvant estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant estramustine and etoposide treatment.
Study: 11182337
Drug: Neoadjuvant estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant estramustine and etoposide treatment followed by radical prostatectomy.
Study: 9216132
Drug: Closed-loop drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop drug infusion using arbutamine
Study: 3524307
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg orally and metoclopramide 10 mg intravenously
Study: 3524307
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg orally and metoclopramide 20 mg intravenously
Study: 27093976
Drug: Pixantrone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixantrone 50 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Study: 27093976
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Study: 12938827
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg at bedtime
Study: 10732179
Drug: Computer-aided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-aided treatment (high technology)
Study: 10732179
Drug: Traditional brush
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional brush machine treatment (low technology)
Study: 1633517
Drug: Total paracentesis
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total paracentesis plus intravenous albumin infusion
Study: 31783136
Drug: Sheng-Hua-Tang (SHT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sheng-Hua-Tang (SHT) 200 mg/kg orally for seven consecutive days
Study: 31751400
Drug: Community-based action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based action teams to change social norms on gender and violence; specific dosage and duration not mentioned.
Study: 28903842
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment on first postoperative day
Study: 25649209
Drug: QMF149 (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 (indacaterol maleate 500 µg/MF 400 µg)
Study: 25649209
Drug: MF (400 µg)
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF (400 µg)
Study: 22584133
Drug: Insulin suspension
Normalized name: Insulin Suspension Isophane (NPH) (Recombinant)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suspension activated by the LGS function
Study: 17383995
Drug: Intravenous dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dopamine (5 microg/kg/min)
Study: 17383995
Drug: Intravenous dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dopamine (10 microg/kg/min)
Study: 11768276
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored treatment (n = 38)
Study: 25321951
Drug: Wavefront-guided (WFG)
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wavefront-guided (WFG) PRK treatment
Study: 25321951
Drug: Wavefront-optimized (WFO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wavefront-optimized (WFO) PRK treatment
Study: 22716199
Drug: Patient-centered collaborative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered collaborative care (CC)
Study: 22716199
Drug: Standard collaborative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard collaborative care (CC)
Study: 12685616
Drug: niacin ER/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin ER/lovastatin 2,000/40 mg
Study: 12685616
Drug: lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 40 mg
Study: 11552018
Drug: OXC 2400
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OXC 2400 mg/day
Study: 11552018
Drug: OXC 300
Normalized name: oxcarbazepine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXC 300 mg/day
Study: 1587075
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg sustained-release fenfluramine plus 15 mg phentermine resin
Study: 1587075
Drug: Initial receipt
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial receipt of medication (fenfluramine plus phentermine)
Study: 1587075
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (fenfluramine plus phentermine)
Study: 4028808
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline ('Trental' 400) 3 times daily for 8 weeks
Study: 4028808
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg co-dergocrine mesylate 3 times daily for 8 weeks
Study: 26924405
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional carbon dioxide laser combined with intradermal platelet-rich plasma treatment
Study: 26924405
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional carbon dioxide laser with intradermal normal saline
Study: 19874728
Drug: Antihistamines, antihistamine‐decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines, antihistamine‐decongestant combinations, guaifenesin
Study: 19874728
Drug: Antihistamines, decongestants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines, decongestants, DM, or combinations
Study: 14612894
Drug: Gemcitabine (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (fixed dose rate schedule)
Study: 11087784
Drug: Sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroacetate (single infusion)
Study: 25273343
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and capecitabine (bevacizumab 15 mg/kg on day 1; capecitabine 1000 mg/m2 twice per day on days 1-14, every 3 weeks)
Study: 25273343
Drug: Bevacizumab only
Normalized name: Bevacizumab only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab only (15 mg/kg on day 1)
Study: 19934097
Drug: Conventional catheters
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheters (CC)
Study: 15767470
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg) for 12 weeks